We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GSK today announced it has submitted a Biologics License Application to the US Food and Drug Administration for Priorix (Measles, Mumps, and Rubella Virus Vaccine, Live) and is seeking approval for use in active immunization against infection by MMR.